Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
NCT ID: NCT06904287
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
100 participants
INTERVENTIONAL
2025-12-16
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines
NCT05967442
Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine
NCT07147972
Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine
NCT01629329
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
NCT04726592
Caffeine/Propranolol Intervention for Acute Migraine
NCT01080677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Drug
Prochlorperazine 10 mg followed by Magnesium 2 g
Magnesium
Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes
Control Arm
Prochlorperazine 10 mg followed by placebo
Placebo
Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnesium
Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes
Placebo
Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide informed consent
* English speaking
* Primary diagnosis of migraine. Patient with a previous diagnosis of migraine, who experience headaches with typical migraine features (e.g at least 2-3 of the following: recurrent, unilateral, pounding or throbbing in nature, associated with nausea), AND with a clinical exclusion of migraine mimics
Exclusion Criteria
* Allergy or sensitivity to study drug
* Stated history of renal insufficiency
* Documented history of myasthenia gravis
* Consumption of study drug within 48 hours prior to enrollment
* Previously enrolled in this trial during a different patient encounter
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ryan McKillip, MD
Role: PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advocate Christ Medical Center Emergency Department
Oak Lawn, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00127959
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.